📌 Introduction and Regulatory Context
The Quality Management System Regulation (QMSR) is the Food and Drug Administration’s (FDA) new regulation, which, as of February 2, 2026, replaces the former Quality System Regulation (QSR) codified in 21 CFR Part 820.
This reform aims to modernize U.S. requirements for current good manufacturing practices (CGMP) applicable to medical devices and to bring them more in line with international standards.
The QMSR incorporates by reference the ISO 13485:2016 standard (Medical devices — Quality management systems — Requirements for regulatory purposes) as well as certain definitions from ISO 9000:2015.
🎯 Objectives and Scope of the QMSR
The main objective of the reform is to promote international regulatory harmonization, while maintaining the specific requirements set forth in the Federal Food, Drug, and Cosmetic Act (FD&C Act).
Scope of Application
The QMSR applies to:
- Manufacturers of finished medical devices intended for sale in the United States;
- Manufacturers of accessories, when such accessories meet the definition of “finished device.”
Devices marketed under an Investigational Device Exemption (IDE) are not exempt from the design and development requirements set forth in ISO 13485 and the QMSR.
In the event of a conflict between ISO 13485 and U.S. regulations, the provisions of the FD&C Act shall prevail.
🔄 Key Changes Compared to the QSR
1. Adoption of ISO 13485:2016
The QMSR fully adopts the requirements of ISO 13485:2016 through a mechanism of incorporation by reference (IBR).
In particular, this involves:
- A structured approach to the device’s life cycle;
- Greater integration of risk management;
- Greater formalization of requirements related to documentation, internal audits, and post-marketing surveillance.
The FDA notes, however, that ISO 13485 certification is not required to demonstrate regulatory compliance with the QMSR.
🔍 2. Expanded access to quality recordings
One notable change concerns access to quality records. Unlike the former 21 CFR 820.180(c), the following records are no longer exempt from inspection:
- Internal Audit Reports
- Management Review Minutes
- Supplier Audit Reports
These records may now be reviewed by the FDA during inspections.
🏢 3. New FDA Inspection Framework
Since the QMSR took effect, the FDA no longer uses the QSIT (Quality System Inspection Technique) approach. Inspections are now conducted according to an updated compliance program aligned with the ISO 13485 framework.
Inspectors may examine:
- Applications submitted before February 2, 2026;
- Documentation demonstrating the transition to the QMSR.
📝 Conclusion
The QMSR marks a transformation of the U.S. regulatory framework for medical devices. The implementation of the QMSR represents:
- An opportunity for global harmonization of quality systems;
- A potential reduction in duplication of effort for manufacturers already certified to ISO 13485;
- Greater regulatory consistency between the United States and other jurisdictions.
In connection with the implementation of the QMSR, medical device manufacturers must conduct a gap analysis between their current quality system (historically aligned with the QSR (21 CFR Part 820)) and the requirements resulting from the incorporation of ISO 13485:2016 into the new regulatory framework.
The FDA specifies that manufacturers must be able to demonstrate that they have successfully transitioned to the QMSR. A structured and documented analysis is therefore a key component of inspection preparation.
Isocèle Conseil supports manufacturers through this regulatory transition, from conducting a gap analysis to the full operational implementation of the QMSR, including document structuring, process alignment, team training, and preparation for inspections.
For more information: https://www.federalregister.gov/documents/2024/02/02/2024-01709/medical-devices-quality-system-regulation-amendments#h-47